Assistive devices coverage
This article was originally published in The Gray Sheet
Independence Through Enhancement of Medicare & Medicaid (ITEM) coalition hopes to increase coverage of assistive device technologies by working to expand recognition of the value of "functionality" improvement and "quality of life" provided. ITEM also will seek to raise awareness and build support for policies that improve access to assistive devices, including mobility, hearing and vision aids, prosthetics and orthotics [Editor's note: For more detailed coverage of the assistive devices coalition agenda, go to 1www.GlobalDeviceReimbursement.com]...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.